Nateglinide, a new mealtime glucose regulator. Lack of pharmacokinetic interaction with digoxin in healthy volunteers

Clinical Drug Investigation

Volumn 19, Issue 6, 2000, Pages 465-471

  Zhou, Honghui ^a   Walter, Yulia H ^a   Smith, Harold ^a   Devineni, Damayanthi ^a   McLeod, James F ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

DIGOXIN; GLUCOSE; NATEGLINIDE;

ADULT; ARTICLE; BLOOD PRESSURE; CLINICAL TRIAL; CROSSOVER PROCEDURE; DIABETES MELLITUS; DRUG SAFETY; ELECTROCARDIOGRAM; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; PHARMACOKINETICS; PRIORITY JOURNAL; SIDE EFFECT;

EID: 0034126691     PISSN: 11732563     EISSN: None     Source Type: Journal    
DOI: 10.2165/00044011-200019060-00009     Document Type: Article

References (14)

1. 1. Aronow WS, Ahn C. Incidence of heart failure in 2,737 older persons with and without diabetes mellitus. Chest 1999; 115 (3): 867-8
2. 2. Reuring RH, Geraets DR, Digoxin. In: Evans WE, Schentag JJ, Jusko WJ, editors. Applied pharmacokinetics. 2nd ed. Washington: Applied Therapeutics, 1986: 570-623
3. 3. Miura T, Ueno K, Tanaka K, et al. Impairment of absorption of digoxin by acarbose. J Clin Pharmacol 1998; 38 (7): 654-7
4. 4. Ben-Ami H, Krivoy N, Nagachandran P, et al. An interaction between digoxin and acarbose. Diabetes Care 1999; 22 (5): 860-1
5. 5. Serrano JS, Jimenez CM, Serrano MI, et al. A possible interaction of potential clinical interest between digoxin and acarbose. Clin Pharmacol Ther 1996; 60 (5): 589-92
6. 6. Boyd RA, Stern RH, Stewart BH, et al. Atorvastatin coadministration may increase digoxin concentrations by inhibition of intestinal P-glycoprotein-mediated secretion. J Clin Pharmacol 2000; 40 (1): 91-8
7. 7. Verschraagen M, Koks CHW, Schellens JHM, et al. P-glycoprotein system as a determinant of drug interactions: the case of digoxin-verapamil. Pharmacol Res 1999; 40 (4): 301-6
8. 8. Fromm MF, Kim RB, Siein CM, et al. Inhibition of P-glycoprotein-mediated drug transport: a unifying mechanism to explain the interaction between digoxin and quinidine. Circulation 1999; 99 (4): 552-7
9. 9. Shinkai H, Toi K, Kumashiro I, et al. N-Acylphenylalanines and related compounds. A new class of oral hypoglycemic agents. J Med Chem 1988; 31: 2092-7
10. 10. Karara AH, Dunning BE, McLeod JF. The effect of food on the oral bioavailability and the pharmacodynamic actions of the insulinotropic agent nateglinide in healthy subjects. J Clin Pharmacol 1999; 39: 172-9
11. 11. Hirschberg Y, Karara AH, Pietri AO, et al. Improved control of mealtime glucose excursion with coadministration of nateglinide and metformin. Diabetes Care 2000; 23: 349-53
12. 12. Keilson L, Mather S, Walter YH, et al. Synergistic effects of nateglinide and meal administration on insulin secretion in patients with type 2 diabetes mellitus. J Clin Endocrinol Melub 2000; 85: 1081-6
13. ATP channel in β-cells: comparison to glyburide and repaglinide [abstract]. Diabetologia 1998; 41 Suppl. I: A139
14. 14. Cohen A, Kroon R, Seamaker R, et al. The bioavailability of digoxin from three oral formulations measured by specific HPLC assay. Br J Clin Pharmacol 1993; 35: 136-42